White House affirms deal on drug cost
New York Times, August 6, 2009
Pressed by industry lobbyists, White House officials have assured drug makers that the administration stood by a behind-the-scenes deal to block any Congressional effort to extract cost savings from them beyond an agreed-upon $80 billion. Drug industry lobbyists reacted with alarm to a House healthcare overhaul measure that would allow the government to negotiate drug prices and demand additional rebates from drug manufacturers. In response, the industry successfully demanded that the White House explicitly acknowledge for the first time that it had committed to protect drug makers from bearing further costs in the overhaul.
- 5 Hot Healthcare Ideas from SXSW
- Hospital CEO Turnover Hits Record High
- Why Is Healthcare Price Transparency So Hard?
- EHR Spending Continues, But Jury Still Out on ROI
- 4 Marketing Tactics for Hospitals on Instagram
- Hospital Groups Strike Back at Hospital Rating Systems
- Care Coordination a Cost-Cutting Quality Driver
- Adverse Events from Insulin Prescribing 'An Epidemic'
- Lahey Health Reexamines the Appropriate Care Model
- Payers Detail Strategies That Drive Consumer Satisfaction